Shares of Argos Therapeutics Inc (NASDAQ:ARGS) have been given an average recommendation of “Hold” by the six ratings firms that are covering the company. Four analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $4.47.
Several equities analysts recently commented on ARGS shares. Stifel Nicolaus dropped their price target on shares of Argos Therapeutics to $1.20 and set a “hold” rating for the company in a research report on Friday, March 17th. Zacks Investment Research lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 7th. FBR & Co reaffirmed a “buy” rating and set a $13.00 price target on shares of Argos Therapeutics in a research report on Tuesday, January 17th. JMP Securities lowered shares of Argos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 22nd. Finally, Needham & Company LLC lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 22nd.
WARNING: This report was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://transcriptdaily.com/2017/04/22/argos-therapeutics-inc-args-receives-10-07-average-pt-from-brokerages.html.
Several large investors have recently added to or reduced their stakes in ARGS. Wasatch Advisors Inc. boosted its stake in shares of Argos Therapeutics by 35.2% in the third quarter. Wasatch Advisors Inc. now owns 3,228,741 shares of the biopharmaceutical company’s stock valued at $16,047,000 after buying an additional 840,260 shares in the last quarter. State Street Corp boosted its stake in shares of Argos Therapeutics by 11.7% in the fourth quarter. State Street Corp now owns 177,494 shares of the biopharmaceutical company’s stock valued at $870,000 after buying an additional 18,625 shares in the last quarter. Finally, Sanders Morris Harris Inc. boosted its stake in shares of Argos Therapeutics by 109.9% in the third quarter. Sanders Morris Harris Inc. now owns 241,512 shares of the biopharmaceutical company’s stock valued at $1,201,000 after buying an additional 126,475 shares in the last quarter. 15.25% of the stock is owned by institutional investors.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
